{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:40:59Z","timestamp":1792190459157,"version":"4.4.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Intrahepatic cholangiocarcinoma (ICC) is highly invasive and carries high mortality due to limited therapeutic strategies. In other solid tumors, immune checkpoint inhibitors (ICIs) target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD1), and the PD1 ligand PD-L1 has revolutionized treatment and improved outcomes. However, the relationship and clinical significance of CTLA-4 and PD-L1 expression in ICC remains to be addressed. Deciphering CTLA-4 and PD-L1 interactions in ICC enable targeted therapy for this disease. In this study, immunohistochemistry (IHC) was used to detect and quantify CTLA-4, forkhead box protein P3 (FOXP3), and PD-L1 in samples from 290 patients with ICC. The prognostic capabilities of CTLA-4, FOXP3, and PD-L1 expression in ICC were investigated with the Kaplan\u2013Meier method. Independent risk factors related to ICC survival and recurrence were assessed by the Cox proportional hazards models. Here, we identified that CTLA-4<jats:sup>+<\/jats:sup> lymphocyte density was elevated in ICC tumors compared with peritumoral hepatic tissues (<jats:italic>P<\/jats:italic> &amp;lt;.001), and patients with a high density of CTLA-4<jats:sup>+<\/jats:sup> tumor-infiltrating lymphocytes (TILs<jats:sup>CTLA-4 High<\/jats:sup>) showed a reduced overall survival (OS) rate and increased cumulative recurrence rate compared with patients with TILs<jats:sup>CTLA-4 Low<\/jats:sup> (<jats:italic>P<\/jats:italic> &amp;lt;.001 and <jats:italic>P<\/jats:italic> = .024, respectively). Similarly, patients with high FOXP3<jats:sup>+<\/jats:sup> TILs (TILs<jats:sup>FOXP3 High<\/jats:sup>) had poorer prognoses than patients with low FOXP3<jats:sup>+<\/jats:sup> TILs (<jats:italic>P<\/jats:italic>\u00a0= .021, <jats:italic>P<\/jats:italic> = .034, respectively), and the density of CTLA-4<jats:sup>+<\/jats:sup> TILs was positively correlated with FOXP3<jats:sup>+<\/jats:sup> TILs (Pearson <jats:italic>r<\/jats:italic> = .31, <jats:italic>P<\/jats:italic> &amp;lt;.001). Furthermore, patients with high PD-L1 expression in tumors (Tumor<jats:sup>PD-L1 High<\/jats:sup>) and\/or TILs<jats:sup>CTLA-4 High<\/jats:sup> presented worse OS and a higher recurrence rate than patients with TILs<jats:sup>CTLA-4 Low<\/jats:sup>Tumor<jats:sup>PD-L1 Low<\/jats:sup>. Moreover, multiple tumors, lymph node metastasis, and high Tumor<jats:sup>PD-L1<\/jats:sup>\/TILs<jats:sup>CTLA-4<\/jats:sup> were independent risk factors of cumulative recurrence and OS for patients after ICC tumor resection. Furthermore, among ICC patients, those with hepatolithiasis had a higher expression of CTLA-4 and worse OS compared with patients with HBV infection or undefined risk factors <jats:italic>(P<\/jats:italic> = .018). In conclusion, CTLA-4 is increased in TILs in ICC and has an expression profile distinct from PD1\/PD-L1. Tumor<jats:sup>PD-L1<\/jats:sup>\/TILs<jats:sup>CTLA-4<\/jats:sup> is a predictive factor of OS and ICC recurrence, suggesting that combined therapy targeting PD1\/PD-L1 and CTLA-4 may be useful in treating patients with ICC.<\/jats:p>","DOI":"10.3389\/fimmu.2021.705378","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T16:39:07Z","timestamp":1630687147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["CTLA-4 Synergizes With PD1\/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiao-Jun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Man","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Zi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Long","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Bin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Wu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 Engagement Inhibits IL-2 Accumulation and Cell Cycle Progression Upon Activation of Resting T Cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and Cellular Functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 Control Over Foxp3+ Regulatory T Cell Function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/CMR.0000000000000305","article-title":"High Cytotoxic T-Lymphocyte-Associated Antigen 4 and Phospho-Akt Expression in Tumor Samples Predicts Poor Clinical Outcomes in Ipilimumab-Treated Melanoma Patients","volume":"27","author":"Chakravarti","year":"2017","journal-title":"Melanoma Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70341-9","article-title":"NICE Guidance on Ipilimumab for Treating Previously Untreated Advanced (Unresectable or Metastatic) Melanoma","volume":"15","author":"Hall","year":"2014","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the Tumor Microenvironment in PD-L1\/PD-1-Mediated Tumor Immune Escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 Expression in the Tumor Microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650481","article-title":"Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors","volume":"11","author":"Zeng","year":"2021","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 Blockade Drives Loss of Treg Stability in Glycolysis-Low Tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab Versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","article-title":"Intrahepatic Cholangiocarcinoma: Epidemiology, Risk Factors, Diagnosis and Surgical Management","volume":"379","author":"Zhang","year":"2016","journal-title":"Cancer Lett"},{"key":"B17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2004.03.018","article-title":"Clinicopathologic Features and Prognosis of Combined Hepatocellular Cholangiocarcinoma","volume":"189","author":"Koh","year":"2005","journal-title":"Am J Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, Cisplatin, and Nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.36276","article-title":"Distinct PD-L1\/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients With Different Risk Factors","volume":"9","author":"Lu","year":"2019","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.034","article-title":"Anti-PD1 Antibody Toripalimab, Lenvatinib and Gemox Chemotherapy as First-Line Treatment of Advanced and Unresectable Intrahepatic Cholangiocarcinoma: A Phase II Clinical Trial","volume":"31","author":"Zhou","year":"2020","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-85156-8","volume-title":"Histological Typing of Tumours of the Liver","author":"Ishak","year":"1994"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23661","article-title":"CD151 Modulates Expression of Matrix Metalloproteinase 9 and Promotes Neoangiogenesis and Progression of Hepatocellular Carcinoma","volume":"52","author":"Shi","year":"2010","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0474-1","article-title":"Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy","volume":"12","author":"Lim","year":"2017","journal-title":"Target Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079490","article-title":"Control of Regulatory T Cell Development by the Transcription Factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80480-x","article-title":"Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR Engagement","volume":"4","author":"Linsley","year":"1996","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","article-title":"Confusing Signals: Recent Progress in CTLA-4 Biology","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T Cells in Cancer Immunosuppression - Implications for Anticancer Therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity Through Reduction of Intratumoral Regulatory T Cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2596","article-title":"CD4\/CD8 + T Cells, DC Subsets, Foxp3, and IDO Expression are Predictive Indictors of Gastric Cancer Prognosis","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000351473","article-title":"FOXP3 Expression is Related to High Ki-67 Index and Poor Prognosis in Lymph Node-Positive Breast Cancer Patients","volume":"85","author":"Kim","year":"2013","journal-title":"Oncology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/82_2017_61","article-title":"CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation","volume":"410","author":"Chikuma","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12938","article-title":"Braking Bad: Novel Mechanisms of CTLA-4 Inhibition of T Cell Responses","volume":"14","author":"Krummey","year":"2014","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on Both Effector and Regulatory T Cell Compartments Contributes to the Antitumor Activity of Anti-CTLA-4 Antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02387-7","article-title":"Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Expression in Chordoma and Tumor-Infiltrating Lymphocytes (TILs) Predicts Prognosis of Spinal Chordoma","volume":"22","author":"He","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095","article-title":"Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7150\/thno.43507","article-title":"Autophagy-Lysosome Inhibitor Chloroquine Prevents CTLA-4 Degradation of T Cells and Attenuates Acute Rejection in Murine Skin and Heart Transplantation","volume":"10","author":"Cui","year":"2020","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.192","article-title":"Perforin and Interferon-Gamma Activities Independently Control Tumor Initiation, Growth, and Metastasis","volume":"97","author":"Street","year":"2001","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1211-y","article-title":"Evaluation of CTLA-4 Expression and Relevance as a Novel Prognostic Factor in Patients With Non-Small Cell Lung Cancer","volume":"61","author":"Salvi","year":"2012","journal-title":"Cancer Immunol Immun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21155","article-title":"CTLA-4 is Constitutively Expressed on Tumor Cells and can Trigger Apoptosis Upon Ligand Interaction","volume":"117","author":"Contardi","year":"2005","journal-title":"Int J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 Cis-Heterodimer Triggers the Co-Stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 Function by Cis-PD-L1\/CD80 Interactions is Required for Optimal T Cell Responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 Pathway in Tolerance and Autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.705378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T16:39:12Z","timestamp":1630687152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.705378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2021.705378"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.705378","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"article-number":"705378"}}